ArticleHealthcare policy = Politiques de sante2007
The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada.
Article in Healthcare policy = Politiques de sante, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A Comparative Study on Different Pharmaceutical Industries and Proposing a Model for the Context of Iran.Iranian journal of pharmaceutical research : IJPR · 2018Article
- Can patent duration hinder medical innovation.International journal of health economics and management · 2016Article
- A review of the health and economic implications of patent protection, with a specific focus on Thailand.Health research policy and systems · 2012Review
- Canadian pharmacare: looking back, looking forward.Healthcare policy = Politiques de sante · 2012Article
- The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.Healthcare policy = Politiques de sante · 2008Article
- The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.Healthcare policy = Politiques de sante · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While pharmaceutical patent terms have increased in Canada, increases in patented drug spending have been mitigated by price controls and retrenchment of public prescription drug subsidy programs. We estimate the net effects of these offsetting policies on domestic pharmaceutical R&D expenditures and also provide an upper-bound estimate on the effects of these policies on Canadian pharmaceutical spending over the period 1988-2002. We estimate that R&D spending increased by $4.4 billion (1997 dollars). Drug spending increased by $3.9 billion at most and, quite likely, by much less. Cutbacks to public drug subsidies and the introduction of price controls likely mitigated drug spending growth. In cost-benefit terms, we suspect that the patent extension policies have been beneficial to Canada.
Identifiers
19305720PMC2585454What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.